Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02464137

HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer — HYDRA  

Squamous Cell Carcinoma of the Larynx Clinical Trial

Official title:
A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

Clinical Trial Summary

single-modality phase I dose escalation toxicity study for first-line curative treatment of head and neck squamous cell carcinoma.

Clinical Trial Description

HYDRA will consist of 5 fraction SBRT treatment targeting only grossly evident disease localized by examination and standard diagnostic CT, MR, and PET-CT imaging. Prophylactic coverage of uninvolved at-risk mucosal and nodal drainage basins will be strictly disallowed. The initial dose cohort will be treated to a total of 42.5 Gy in five equal fractions delivered every other day over a two week period (biologically equivalent to 66 Gy delivered in 2 Gy daily fractions), drawn from our successful institutional experience with similar dosing and fractionation for early-stage larynx SBRT. Escalation of total dose will proceed in 2.5 Gy increments, up to a final target dose of 50 Gy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02464137
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Terminated
Phase Phase 1
Start date April 27, 2015
Completion date March 4, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Not yet recruiting NCT06137378 - European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] Phase 2
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Not yet recruiting NCT05752149 - Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial Phase 2
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Withdrawn NCT04831450 - Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03114462 - Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer Phase 1